Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNLINASDAQ:KNSANASDAQ:KYMRNASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$13.42-1.8%$13.97$10.57▼$33.33$1.95B1.491.10 million shs786,274 shsKNSAKiniksa Pharmaceuticals$26.89+3.6%$23.26$17.38▼$28.56$1.96B0.07487,154 shs590,247 shsKYMRKymera Therapeutics$29.49-2.3%$28.96$19.45▼$53.27$1.92B2.18561,761 shs352,793 shsTYRATyra Biosciences$9.29-3.1%$9.43$6.42▼$29.60$493.21M1.17263,849 shs189,305 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics-1.76%-2.61%-9.81%-35.34%-33.10%KNSAKiniksa Pharmaceuticals+3.62%+2.44%+28.78%+34.32%+39.54%KYMRKymera Therapeutics-2.25%-2.51%-3.94%-19.89%-17.39%TYRATyra Biosciences-3.13%-7.01%-7.29%-29.46%-47.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNLIDenali Therapeutics4.4771 of 5 stars4.53.00.04.73.21.70.0KNSAKiniksa Pharmaceuticals2.9576 of 5 stars3.52.00.00.03.63.30.6KYMRKymera Therapeutics2.7516 of 5 stars4.42.00.00.02.91.70.0TYRATyra Biosciences1.6651 of 5 stars3.50.00.00.02.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNLIDenali Therapeutics 3.06Buy$33.71151.22% UpsideKNSAKiniksa Pharmaceuticals 3.00Buy$38.8044.29% UpsideKYMRKymera Therapeutics 2.82Moderate Buy$55.2587.35% UpsideTYRATyra Biosciences 3.00Buy$30.83231.90% UpsideCurrent Analyst Ratings BreakdownLatest TYRA, DNLI, KYMR, and KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/21/2025TYRATyra BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$33.005/20/2025KYMRKymera TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$55.005/19/2025DNLIDenali TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $27.005/13/2025KYMRKymera TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$72.00 ➝ $70.005/12/2025KYMRKymera TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$47.00 ➝ $44.005/12/2025KYMRKymera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$52.00 ➝ $52.005/8/2025DNLIDenali TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $29.005/7/2025DNLIDenali TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.005/7/2025DNLIDenali TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $32.004/29/2025KNSAKiniksa PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$40.00 ➝ $45.004/24/2025DNLIDenali TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNLIDenali Therapeutics$330.53M5.90N/AN/A$7.42 per share1.81KNSAKiniksa Pharmaceuticals$481.17M4.08N/AN/A$6.23 per share4.32KYMRKymera Therapeutics$58.89M32.61N/AN/A$7.12 per share4.14TYRATyra BiosciencesN/AN/AN/AN/A$4.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNLIDenali Therapeutics-$145.22M-$2.67N/AN/AN/AN/A-32.94%-30.04%8/7/2025 (Estimated)KNSAKiniksa Pharmaceuticals$14.08M-$0.25N/A107.56N/A-2.36%-7.31%-5.95%7/22/2025 (Estimated)KYMRKymera Therapeutics-$146.96M-$3.10N/AN/AN/A-191.26%-24.96%-20.27%8/6/2025 (Estimated)TYRATyra Biosciences-$69.13M-$1.63N/AN/AN/AN/A-24.56%-23.31%8/6/2025 (Estimated)Latest TYRA, DNLI, KYMR, and KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million5/8/2025Q1 2025TYRATyra Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A5/6/2025Q1 2025DNLIDenali Therapeutics-$0.71-$0.78-$0.07-$0.78$3.24 millionN/A4/29/2025Q1 2025KNSAKiniksa Pharmaceuticals$0.02$0.11+$0.09$0.11$128.35 million$137.79 million3/27/2025Q4 2024TYRATyra Biosciences-$0.48-$0.43+$0.05-$0.43N/AN/A2/27/2025Q4 2024DNLIDenali Therapeutics-$0.75-$0.67+$0.08-$0.67$12.75 millionN/A2/27/2025Q4 2024KYMRKymera Therapeutics-$0.76-$0.88-$0.12-$0.88$14.81 million$7.39 million2/25/2025Q4 2024KNSAKiniksa Pharmaceuticals-$0.06-$0.12-$0.06-$0.12$123.42 million$122.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNLIDenali TherapeuticsN/AN/AN/AN/AN/AKNSAKiniksa PharmaceuticalsN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNLIDenali TherapeuticsN/A9.989.98KNSAKiniksa PharmaceuticalsN/A3.242.95KYMRKymera TherapeuticsN/A8.558.55TYRATyra BiosciencesN/A29.5529.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNLIDenali Therapeutics92.92%KNSAKiniksa Pharmaceuticals53.95%KYMRKymera TherapeuticsN/ATYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipDNLIDenali Therapeutics7.90%KNSAKiniksa Pharmaceuticals54.57%KYMRKymera Therapeutics16.01%TYRATyra Biosciences15.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNLIDenali Therapeutics430145.28 million132.55 millionOptionableKNSAKiniksa Pharmaceuticals22072.97 million32.80 millionOptionableKYMRKymera Therapeutics17065.12 million54.52 millionOptionableTYRATyra Biosciences2053.09 million42.81 millionOptionableTYRA, DNLI, KYMR, and KNSA HeadlinesRecent News About These CompaniesTyra Biosciences (NASDAQ:TYRA) Now Covered by Piper SandlerMay 23 at 10:11 AM | marketbeat.comHC Wainwright Has Optimistic Outlook of TYRA FY2025 EarningsMay 23 at 8:29 AM | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Coverage Initiated at Piper SandlerMay 23 at 1:27 AM | americanbankingnews.comEquities Analysts Offer Predictions for TYRA FY2026 EarningsMay 22 at 7:40 AM | marketbeat.comFY2025 EPS Forecast for Tyra Biosciences Boosted by AnalystMay 22 at 1:51 AM | americanbankingnews.comVestal Point Capital LP Makes New Investment in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 21 at 8:14 AM | marketbeat.comDimensional Fund Advisors LP Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 19, 2025 | marketbeat.comJanus Henderson Group PLC Has $24.29 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 18, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Purchases Shares of 244,245 Tyra Biosciences, Inc. (NASDAQ:TYRA)May 17, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Shares Acquired by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comCubist Systematic Strategies LLC Takes $1.53 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 15, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.83 Average PT from BrokeragesMay 15, 2025 | americanbankingnews.comTyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of "Buy" by BrokeragesMay 13, 2025 | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPSMay 12, 2025 | marketbeat.comTyra Biosciences to Participate at Upcoming Investor ConferencesMay 12, 2025 | prnewswire.comFarallon Capital Management LLC Invests $13.91 Million in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 11, 2025 | marketbeat.comOne Tyra Biosciences Insider Raised Stake By 284% In Previous YearMay 9, 2025 | finance.yahoo.com54,783 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Acquired by Raymond James Financial Inc.May 9, 2025 | marketbeat.comTyra Biosciences Reports First Quarter 2025 Financial Results and HighlightsMay 8, 2025 | prnewswire.comWhy Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.48%May 6, 2025 | aaii.comTyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by BVF Inc. ILMay 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTYRA, DNLI, KYMR, and KNSA Company DescriptionsDenali Therapeutics NASDAQ:DNLI$13.42 -0.24 (-1.76%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$13.66 +0.23 (+1.75%) As of 05/23/2025 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Kiniksa Pharmaceuticals NASDAQ:KNSA$26.89 +0.94 (+3.62%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$26.90 +0.00 (+0.02%) As of 05/23/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Kymera Therapeutics NASDAQ:KYMR$29.49 -0.68 (-2.25%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$29.10 -0.39 (-1.32%) As of 05/23/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Tyra Biosciences NASDAQ:TYRA$9.29 -0.30 (-3.13%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.30 +0.01 (+0.05%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
